TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07824622: A Phase I, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Pharmacokinetics of AZD0543 in Healthy Adults

Sponsor: AstraZeneca · Phase: PHASE1 · Area: INFECTIOUS_VACCINE · Target Enrollment: 144 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$6,397,440

Rescue Site Savings

+$4,218,312

Unlock Full NCT07824622 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07824622 Rescue Dossier →